Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6330781 | 0.86 | KDR (0.52) | KDRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6330948 | 0.78 | KDR (0.68) | KDR | |
| SCHEMBL5743358 | 0.75 | KDR (0.48) | KDR | |
| SCHEMBL5742162 | 0.73 | KDR (0.49) | KDR | |
| SCHEMBL5744443 | 0.72 | KDR (0.56) | KDR | |
| SCHEMBL7228107 | 0.70 | KDR (0.55) | KDR | |
| SCHEMBL6332164 | 0.69 | KDR (0.45) | KDR | |
| SCHEMBL6330170 | 0.68 | KDR (0.65) | KDRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5741877 | 0.68 | KDR (0.61) | KDR | |
| SCHEMBL7237383 | 0.68 | KDR (0.63) | KDRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050228031-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T | 2005-10-13 | — | — | US | claimed |
| US-20050228031-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228031-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885NPC1 3497/4885RAB9A 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.